AP9600883A0 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number: AP9600883A0
Authority: AP; ARIPO
Prior art keywords: pharmaceutical formulations; formulations; pharmaceutical
Prior art date: 1995-11-21

Application number

AP9600883A

Other versions

AP718A (en

Original Assignee

Pfizer Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-21

Filing date

1996-11-21

Publication date

1997-01-31

1996-11-21 Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev

1997-01-31 Publication of AP9600883A0 publication Critical patent/AP9600883A0/en

1999-01-06 Application granted granted Critical

1999-01-06 Publication of AP718A publication Critical patent/AP718A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

APAP/P/1996/000883A 1995-11-21 1996-11-21 A controlled-release pharmaceutical formulation for oral administration. AP718A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9523752.5A GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations

Publications (2)

Publication Number	Publication Date
AP9600883A0 true AP9600883A0 (en)	1997-01-31
AP718A AP718A (en)	1999-01-06

Family

ID=10784188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1996/000883A AP718A (en)	1995-11-21	1996-11-21	A controlled-release pharmaceutical formulation for oral administration.

Country Status (29)

Country	Link
EP (1)	EP0862437A1 (en)
JP (1)	JPH10513481A (en)
KR (1)	KR19990071505A (en)
CN (1)	CN1215993A (en)
AP (1)	AP718A (en)
AR (1)	AR004335A1 (en)
AU (1)	AU709560B2 (en)
BG (1)	BG102438A (en)
BR (1)	BR9611626A (en)
CA (1)	CA2232715A1 (en)
CO (1)	CO4480020A1 (en)
CZ (1)	CZ155498A3 (en)
GB (1)	GB9523752D0 (en)
HR (1)	HRP960554A2 (en)
HU (1)	HUP9903734A3 (en)
IS (1)	IS4706A (en)
MA (1)	MA26410A1 (en)
MX (1)	MX9804008A (en)
NO (1)	NO982302L (en)
NZ (1)	NZ322053A (en)
OA (1)	OA10687A (en)
PE (1)	PE22898A1 (en)
PL (1)	PL326981A1 (en)
SK (1)	SK63098A3 (en)
TN (1)	TNSN96141A1 (en)
TR (1)	TR199800902T2 (en)
WO (1)	WO1997018814A1 (en)
YU (1)	YU62096A (en)
ZA (1)	ZA969722B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5945125A (en) *	1995-02-28	1999-08-31	Temple University	Controlled release tablet
BR9813699A (en) *	1997-12-16	2000-10-10	Pfizer Prod Inc	Effective combination for the treatment of impotence
WO1999047128A1 (en)	1998-03-19	1999-09-23	Bristol-Myers Squibb Company	Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (en) *	1998-05-15	2000-10-14	Pfizer	PHARMACEUTICAL FORMULATIONS.
EP0974343B1 (en) *	1998-07-22	2004-09-29	Pharma Pass II LLC	Process for manufacturing a solid metoprolol composition
EP0987020A1 (en) *	1998-09-04	2000-03-22	Pharma Pass LLC	Metoprolol composition and processes for manufacturing the same
CO5140079A1 (en) *	1998-10-14	2002-03-22	Novartis Ag	PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
UA67802C2 (en) *	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US20030059467A1 (en) *	2001-09-14	2003-03-27	Pawan Seth	Pharmaceutical composition comprising doxasozin
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) *	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1680078A2 (en) *	2003-10-17	2006-07-19	Ranbaxy Laboratories, Ltd.	Oral matrix formulations of doxazosin
WO2005107702A2 (en) *	2004-05-11	2005-11-17	Glenmark Pharmaceuticals Limited	Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (en) *	2004-05-28	2006-04-27	한미약품 주식회사	Sustained release composition for oral administration of niacin
DE102004054054A1 (en)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
KR100679111B1 (en) *	2004-11-20	2007-02-07	대우약품공업주식회사	Sustained-release tablets containing doxazosin
RU2442574C2 (en) *	2005-08-22	2012-02-20	Новартис Аг	THE PHARMACEUTICAL COMPOSITIONS CONTAINING pH - DEPENDENT MEDICAL PRODUCT, THE pH MODIFIER AND THE SLOWING DOWN AGENT
US20090176882A1 (en)	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
ES2396051T3 (en)	2006-04-26	2013-02-18	Supernus Pharmaceuticals, Inc.	Oxcarbazepine controlled release preparations that have sigmoidal release profile
PE20080251A1 (en)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	USES OF DPP IV INHIBITORS
BRPI0711558A2 (en)	2006-05-04	2011-11-08	Boeringer Ingelheim Internat Gmbh	polymorphs
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CN100396282C (en) *	2006-07-25	2008-06-25	山东省医药工业研究所	Slow released doxazosin mesilate capsule and its prepn process
SA07280459B1 (en)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en)	2008-03-11	2009-09-17	Depomed Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20140960A1 (en)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	FORMULATIONS INVOLVING A DPP4 INHIBITOR
BRPI0916997A2 (en)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	DPP-4 INHIBITOR AND ITS USE
TWI478712B (en)	2008-09-30	2015-04-01	Astellas Pharma Inc	Pharmaceutical composition for modified release
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (en) *	2008-12-17	2010-12-24	동아제약주식회사	Controlled Release Compositions for Preparing Udenafil-Containing Sustained-Release Formulations
MX339194B (en)	2009-02-13	2016-05-16	Boehringer Ingelheim Int	Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof.
US8828953B2 (en)	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
AU2010239311B2 (en)	2009-04-20	2014-05-22	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
EA034869B1 (en)	2009-11-27	2020-03-31	Бёрингер Ингельхайм Интернациональ Гмбх	Treatment of genotyped diabetic patients with dpp-4 inhibitors such as linagliptin
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
MX341025B (en)	2010-05-05	2016-08-04	Boehringer Ingelheim Int Gmbh *	Combination therapy.
RU2596787C2 (en)	2010-07-09	2016-09-10	БиЭйчВи ФАРМА, ИНК.	Combined delivery system with immediate/sustained release of medicinal agents with short period of half-life, including for remogliflozin
BR112013009635A2 (en)	2010-10-19	2016-07-12	Elcelyx Therapeutics Inc	chemosensory receptor ligand-based therapies
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
WO2012094636A2 (en)	2011-01-07	2012-07-12	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
CN102058555A (en) *	2011-01-13	2011-05-18	北京汇诚瑞祥医药技术有限公司	Doxazosin controlled release tablet
AR085689A1 (en)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
CN102188431A (en) *	2011-05-09	2011-09-21	浙江九旭药业有限公司	Doxazosin mesylate sustained-release tablets and preparation method thereof
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en)	2011-05-17	2015-06-09	Mallinckrodt Llc	Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
AU2012345659B2 (en)	2011-12-02	2017-09-28	Synchroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013158928A2 (en)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
JP6224084B2 (en)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014197744A1 (en)	2013-06-05	2014-12-11	Synchroneuron, Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9526728B2 (en)	2014-02-28	2016-12-27	Boehringer Ingelheim International Gmbh	Medical use of a DPP-4 inhibitor
CN105616378A (en) *	2014-10-31	2016-06-01	康普药业股份有限公司	Fluconazole capsule and preparation method therefor
CN109310697A (en)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	Combination of linagliptin and metformin
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1198386B (en) *	1982-07-06	1988-12-21	Lepetit Spa	A PROTRACTED RELEASE PRODUCT CONTAINING SULOCTIDYL
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
IE62597B1 (en) *	1990-07-23	1995-02-08	Alza Corp	Oral osmotic device for delivering nicotine

1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
1996
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-11 CN CN96198486A patent/CN1215993A/en active Pending
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/en unknown
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 PL PL96326981A patent/PL326981A1/en unknown
- 1996-11-11 SK SK630-98A patent/SK63098A3/en unknown
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/en unknown
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/en not_active Ceased
- 1996-11-11 JP JP9519364A patent/JPH10513481A/en active Pending
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Ceased
- 1996-11-11 NZ NZ322053A patent/NZ322053A/en unknown
- 1996-11-11 BR BR9611626A patent/BR9611626A/en not_active Application Discontinuation
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/en unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/en not_active Application Discontinuation
- 1996-11-20 AR ARP960105252A patent/AR004335A1/en unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/en unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/en unknown
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/en unknown
- 1996-11-20 YU YU62096A patent/YU62096A/en unknown
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
- 1996-11-21 CO CO96061449A patent/CO4480020A1/en unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/en not_active Application Discontinuation
1998
- 1998-03-31 IS IS4706A patent/IS4706A/en unknown
- 1998-05-08 BG BG102438A patent/BG102438A/en unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/en unknown
- 1998-05-20 NO NO982302A patent/NO982302L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
BG102438A (en)	1999-01-29
HUP9903734A3 (en)	2000-04-28
NO982302D0 (en)	1998-05-20
AU709560B2 (en)	1999-09-02
CN1215993A (en)	1999-05-05
HRP960554A2 (en)	1998-02-28
NO982302L (en)	1998-07-17
PE22898A1 (en)	1998-05-07
NZ322053A (en)	1999-11-29
AP718A (en)	1999-01-06
GB9523752D0 (en)	1996-01-24
IS4706A (en)	1998-03-31
HUP9903734A2 (en)	2000-03-28
SK63098A3 (en)	1999-05-07
WO1997018814A1 (en)	1997-05-29
BR9611626A (en)	1999-06-01
ZA969722B (en)	1998-05-20
AR004335A1 (en)	1998-11-04
MX9804008A (en)	1998-09-30
CA2232715A1 (en)	1997-05-29
TR199800902T2 (en)	1998-09-21
PL326981A1 (en)	1998-11-09
OA10687A (en)	2002-11-27
CO4480020A1 (en)	1997-07-09
EP0862437A1 (en)	1998-09-09
JPH10513481A (en)	1998-12-22
YU62096A (en)	1999-03-04
TNSN96141A1 (en)	2005-03-15
AU7572196A (en)	1997-06-11
MA26410A1 (en)	2004-12-20
CZ155498A3 (en)	1999-03-17
KR19990071505A (en)	1999-09-27

Publication	Publication Date	Title
EG23826A (en)	2007-09-25	Pharmaceutical formulations
GB9523752D0 (en)	1996-01-24	Pharmaceutical formulations
GB9408117D0 (en)	1994-06-15	Pharmaceutical formulations
GB9519363D0 (en)	1995-11-22	Pharmaceutical formulation
GB9404248D0 (en)	1994-04-20	Pharmaceutical formulations
EP0862431A4 (en)	1999-07-07	Pharmaceutical formulation
ZA967827B (en)	1997-03-18	Pharmaceutical compositions
EG24294A (en)	2009-01-08	Pharmaceutical compositions
GB9506382D0 (en)	1995-05-17	Pharmaceutical compositions
GB9513972D0 (en)	1995-09-06	Pharmaceutical compositions
GB9523566D0 (en)	1996-01-17	Pharmaceutical formulation
ZA96526B (en)	1996-08-06	Novel pharmaceutical formulation
AP9801196A0 (en)	1998-03-31	Pharmaceutical preparation
ZA96392B (en)	1996-08-29	Pharmaceutical formulations
GB9413542D0 (en)	1994-08-24	Pharmaceutical formulations
GB9500978D0 (en)	1995-03-08	Pharmaceutical formulations
ZA967542B (en)	1997-03-20	Pharmaceutical combination preparation comprising keto-profen
GB9503752D0 (en)	1995-04-12	Pharmaceutical formulations
GB9508989D0 (en)	1995-06-21	Pharmaceutical formulations
GB9516584D0 (en)	1995-10-11	Pharmaceutical formulations
HUP9602732A2 (en)	1997-09-29	Pharmaceutical composition comprising lanperisone
GB9408151D0 (en)	1994-06-15	Pharmaceutical formulations
GB9414216D0 (en)	1994-08-31	Pharmaceutical formulations
GB9401738D0 (en)	1994-03-23	Pharmaceutical formulations
GB9408162D0 (en)	1994-06-15	Pharmaceutical formulations